FRI0526 Anti-osteoporotic therapy decrease cancer risk in patients with osteoporotic vertebral fractures

Background Some studies had looked at the long-term effect of anti-osteoporotic therapy on risks of different cancers in the general population. But epidemiological studies have consistently reported a reduced risk of breast cancer in bisphosphonate users. so there is little data to establish definitive conclusions. Objectives This study aimed to determine if anti-osteoporotic therapy can influence cancer risk in patients with osteoporotic vertebral fracture. Methods This retrospective study reviewed of cases of osteoporosis patients with acute vertebral fractures between 2001 and 2015. Anti-osteoporotic therapy were recorded (alendronate, ibandronate, zolendronic acid, raloxifen, teriparatide, denosumab). We followed these patients to develop cancer. All associated co-morbidities were recorded. Cox regression analysis were performed. Results There were 1128 patients with acute vertebral fractures were enrolled, among them 693 patients accepted anti-osteoporotic therapy, 432 were not. The mean age of anti-osteoporotic therapy was 73.86±7.52, while the age of nonanti-osteoporotic therapy was 72.82±10.92 (p=0.059). 15 (2.2%) patients of anti-osteoporotic therapy developed cancer, while 24 (5.6%) patients of non-antiosteoporotic therapy developed cancer (p=0.004). After adjusting for potential confounders, patients with antiosteoporotic therapy still had a lower cancer risk ( p =0.038; HR: 0.428, 95% CI: 0.192∼0.955). The cancer risk also increased among smokers ( p =0.002; HR: 10.505; 95% CI: 2.375∼46.462). Conclusions In this study, anti-osteoporotic therapy decrease cancer risk. So we could safely use these drugs in osteoporotic management. References British Journal of Cancer (2013) 109, 795–806. Acknowledgements We thanked Kaohsiung Chang Gang Memorial hospital for data support. Disclosure of Interest None declared